Mylan, which in 2020 merged with a division of ... leading to dangerous overprescribing and diversion of its opioids into the illegal drug market. Viatris did not admit wrongdoing as part of ...

Mylan, the company that came under fire this summer for systematically raising the price of the EpiPen, is caught up in another drug price scheme. The pharmaceutical player is one of six companies ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could ...

Attorney General Kathy Jennings on Monday announced the multistate settlement with Mylan Inc., which is now part of Viatris, for its role in manufacturing and selling a variety of opioids since 2005.

Bresch will continue to cite Mylan's work on allergy awareness (which had the dual effect of helping to sell more EpiPens) and its work on other drugs, like the HIV medication one audience member ...

The release stated Mylan, a pharmaceutical company that's now ... overprescribing and diversion of its opioids into the illegal drug market. "The company will also continue its longstanding ...

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Mylan, now part of global pharmaceutical company ... The company was accused by states of marketing the drugs as “less prone to abuse” even though it knew the opposite was true, especially ...

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic ...

Mylan — now part of drugmaker Viatris — has ... The attorney generals also claim the company fueled the opioid drug crisis by marketing directly to doctors, leading them to overprescribe.

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...